Nav: Home

Researchers find new potential approach to type 2 diabetes treatment

November 08, 2019

The protein adipsin, which is produced in body fat, helps protect insulin-secreting cells called pancreatic beta cells from destruction in type 2 diabetes, according to a new study by researchers at Weill Cornell Medicine andNewYork-Presbyterian. Among middle-aged adults, higher levels of the protein in the blood were also associated with protection from type 2 diabetes.

The study, published Nov. 7 in Nature Medicine, may have implications for the future development of type 2 diabetes therapies that target and protect beta cells.

"A big problem associated with type 2 diabetes is that beta cells stop functioning properly and fade away," said senior author Dr. James C. Lo, assistant professor of medicine and of pharmacology at Weill Cornell Medicine and a cardiologist at NewYork-Presbyterian/Weill Cornell Medical Center. About 30 million people in the United States have diabetes, and up to 95% of these individuals have the type 2 form of the disease, in which the body stops responding to insulin and pancreatic beta cells slowly stop producing enough of it.

Some of the currently available medications that target beta cells have side effects, such as lowering blood glucose levels too much, said Dr. Lo. In addition, there are no proven treatments to prevent beta cell loss. People with type 2 diabetes whose beta cells don't work properly have to inject insulin to keep their blood glucose levels stable.

The team, which included researchers in the laboratories of Drs. Mingming Hao, Noah Dephoure and Dr. Lukas Dow at Weill Cornell Medicine, knew that adipsin had a role in stimulating beta cells to secrete insulin and theorized that the protein might be a potential therapy for type 2 diabetes.

To explore this theory, the scientists first conducted a study in which they increasedadipsin levels in mice with type 2 diabetes. They found that adipsin had a long-term positive effect on diabetes, improving blood sugar and increasing insulin levels while helping to prevent beta cell death. "Our findings in mice showed that more adipsin in the blood translated to better diabetes control," Dr. Lo said.

Dr. Lo and his collaborators at Icahn School of Medicine at Mount Sinai also studied human beta cells in their laboratories and determined that adipsin activates a molecule called C3a, which protects and supports beta cell function. They further discovered that C3a suppresses an enzyme called Dusp26 that can damage beta cells and cause them to die.

The researchers then directly blocked DUSP26 activity in human beta cells and found that this treatment protected the beta cells from death. Similarly, when they suppressed DUSP26 activity in mice, beta cells became healthier, meaning they could better secrete insulin.

"I hope that both adipsin or DUSP26-directed therapies may prevent type 2 diabetes patients from developing beta cell failure and from requiring insulin injections for their treatment," said lead author Dr. Nicolás Gómez-Banoy, a postdoctoral fellow in Dr. Lo's laboratory.

To gain a better understanding of how adipsinmight be influencing the health of people in the community, the team collaborated with researchers at Harvard Medical School and Massachusetts General Hospital to evaluate 5570 individuals enrolled in the Framingham Heart Study, an ongoing cardiovascular study being conducted in Massachusetts.

The scientists found that people with higher levels of adipsin in the blood had a lower incidence of developing diabetes in the future than people with lower levels. People with the highest level of adipsin had more than a 50% reduction in diabetes incidence compared with people with the lowest level of adipsin.

In addition, adipsin levels correlated with the amount of subcutaneous fat, which is stored just under the skin, rather than visceral fat, stored within the abdomen. "Most people think that fat is associated with something bad, but it's more complicated than that," said Dr. Lo, who is also a member of the Weill Center for Metabolic Health and the Cardiovascular Research Institute at Weill Cornell Medicine. "Subcutaneous fat is more benign or even protective compared to visceral fat."

Further studies are needed to determinewhether a higher level of adipsin in humans protects them from developing diabetes and whether increasing adipsin levels would reduce the risk of developing diabetes in certain populations.

Dr. Lo and his research team are currently investigating whether targeting and inhibitingDUSP26 production in beta cells may be a possible avenue for drug development.

"We hope this could be a novel treatment opportunity," Dr. Lo said.
-end-
Drs. Lo and Gomez-Banoy are named inventors on a provisional patent application filed by Cornell University that covers the use of DUSP26 inhibitors for the treatment of type 2 diabetes.

Weill Cornell Medicine

Related Diabetes Articles:

Tele-diabetes to manage new-onset diabetes during COVID-19 pandemic
Two new case studies highlight the use of tele-diabetes to manage new-onset type 1 diabetes in an adult and an infant during the COVID-19 pandemic.
Genetic profile may predict type 2 diabetes risk among women with gestational diabetes
Women who go on to develop type 2 diabetes after having gestational, or pregnancy-related, diabetes are more likely to have particular genetic profiles, suggests an analysis by researchers at the National Institutes of Health and other institutions.
Maternal gestational diabetes linked to diabetes in children
Children and youth of mothers who had gestational diabetes during pregnancy are at increased risk of diabetes themselves, according to new research published in CMAJ (Canadian Medical Association Journal).
Two diabetes medications don't slow progression of type 2 diabetes in youth
In youth with impaired glucose tolerance or recent-onset type 2 diabetes, neither initial treatment with long-acting insulin followed by the drug metformin, nor metformin alone preserved the body's ability to make insulin, according to results published online June 25 in Diabetes Care.
People with diabetes visit the dentist less frequently despite link between diabetes, oral health
Adults with diabetes are less likely to visit the dentist than people with prediabetes or without diabetes, finds a new study led by researchers at NYU Rory Meyers College of Nursing and East Carolina University's Brody School of Medicine.
Diabetes, but not diabetes drug, linked to poor pregnancy outcomes
New research indicates that pregnant women with pre-gestational diabetes who take metformin are at a higher risk for adverse pregnancy outcomes -- such as major birth defects and pregnancy loss -- than the general population, but their increased risk is not due to metformin but diabetes.
New oral diabetes drug shows promise in phase 3 trial for patients with type 1 diabetes
A University of Colorado Anschutz Medical Campus study finds sotagliflozin helps control glucose and reduces the need for insulin in patients with type 1 diabetes.
Can continuous glucose monitoring improve diabetes control in patients with type 1 diabetes who inject insulin
Two studies in the Jan. 24/31 issue of JAMA find that use of a sensor implanted under the skin that continuously monitors glucose levels resulted in improved levels in patients with type 1 diabetes who inject insulin multiple times a day, compared to conventional treatment.
Complications of type 2 diabetes affect quality of life, care can lead to diabetes burnout
T2D Lifestyle, a national survey by Health Union of more than 400 individuals experiencing type 2 diabetes (T2D), reveals that patients not only struggle with commonly understood complications, but also numerous lesser known ones that people do not associate with diabetes.
A better way to predict diabetes
An international team of researchers has discovered a simple, accurate new way to predict which women with gestational diabetes will develop type 2 diabetes after delivery.
More Diabetes News and Diabetes Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Climate Mindset
In the past few months, human beings have come together to fight a global threat. This hour, TED speakers explore how our response can be the catalyst to fight another global crisis: climate change. Guests include political strategist Tom Rivett-Carnac, diplomat Christiana Figueres, climate justice activist Xiye Bastida, and writer, illustrator, and artist Oliver Jeffers.
Now Playing: Science for the People

#562 Superbug to Bedside
By now we're all good and scared about antibiotic resistance, one of the many things coming to get us all. But there's good news, sort of. News antibiotics are coming out! How do they get tested? What does that kind of a trial look like and how does it happen? Host Bethany Brookeshire talks with Matt McCarthy, author of "Superbugs: The Race to Stop an Epidemic", about the ins and outs of testing a new antibiotic in the hospital.
Now Playing: Radiolab

Speedy Beet
There are few musical moments more well-worn than the first four notes of Beethoven's Fifth Symphony. But in this short, we find out that Beethoven might have made a last-ditch effort to keep his music from ever feeling familiar, to keep pushing his listeners to a kind of psychological limit. Big thanks to our Brooklyn Philharmonic musicians: Deborah Buck and Suzy Perelman on violin, Arash Amini on cello, and Ah Ling Neu on viola. And check out The First Four Notes, Matthew Guerrieri's book on Beethoven's Fifth. Support Radiolab today at Radiolab.org/donate.